ArticleDiscover oncology2025
Expression and prognostic diagnostic significance of RGS gene family in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe Regulator of G Protein Signaling (RGS) gene family, known as critical negative regulators of G protein-coupled receptor (GPCR) signaling pathways, has emerged as a potential therapeutic target in various malignancies. This study aims to comprehensively evaluate the expression profiles of RGS genes in breast cancer, exploring their diagnostic, prognostic, and chemotherapeutic sensitivity-related roles.
methodsPan-cancer RNA-seq data, immune phenotype data, stemness indices, and breast cancer data from the TCGA and GTEx databases (via UCSC Xena) were integrated to analyze the expression patterns of RGS genes across different cancers. Associations with immune microenvironment factors (e.g., stromal and immune scores), tumor stemness (mRNAsi/mDNAsi), and chemotherapy drug sensitivity (cyclophosphamide, neratinib, clobutin, etc.) were assessed. The relationship between RGS gene expression and overall survival (OS) as well as progression-free survival (PFS) in breast cancer patients was analyzed using the KM-Plotter database, leading to the identification of potential diagnostic and prognostic biomarkers.
resultsPan-cancer analyses revealed significant positive correlations between the expression of RGS1, RGS13, RGS18, and RGS19 and both stromal and immune scores (P < 0.05). High expression of RGS18 and RGS19 was associated with increased predicted sensitivity to cyclophosphamide and neratinib. In breast cancer, RGS17, RGS16, and RGS1 demonstrated diagnostic potential for immune subtypes (AUC > 0.65), while RGS10 and RGS16 correlated with tumor stage (P < 0.01). A seven-gene RGS-based signature effectively stratified patients by survival risk, with the high-risk group exhibiting significantly poorer OS and PFS (HR = 1.82, 95% CI 1.34–2.47).
conclusionThe RGS gene family plays a crucial role in breast cancer progression through modulation of the immune microenvironment and chemotherapy resistance. Their expression profiles hold promise as novel biomarkers for personalized prognostic stratification and targeted therapy, particularly for guiding chemotherapy drug selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.